@article{Bachmann_Iding_Lautz_Thomé-Pfeiffer_Maierhofer_Mondière_Schmidt_Strasser_Bär_Aebi_et al._2021, title={Development of the Commercial Manufacturing Process for Ipatasertib}, volume={75}, url={https://www.chimia.ch/chimia/article/view/2021_605}, DOI={10.2533/chimia.2021.605}, abstractNote={<p>Ipatasertib is a potent small molecule Akt kinase inhibitor currently tested in Phase III clinical trials for the treatment of metastatic castration-resistant prostate cancer and triple negative metastatic breast cancer. In this paper an overview of the development achievements towards the commercial manufacturing process is given. The convergent synthesis consists of ten steps with eight isolated intermediates and utilizes a wide range of chemical techniques and technologies to build-up this complex drug. All three stereocenters are introduced using enzyme or metal catalysis.</p>}, number={7-8}, journal={CHIMIA}, author={Bachmann, Stephan and Iding, Hans and Lautz, Christian and Thomé-Pfeiffer, Isabelle and Maierhofer, Caroline and Mondière, Régis and Schmidt, Philipp and Strasser, Christoph and Bär, Thomas and Aebi, André and et al.}, year={2021}, month={Aug.}, pages={605} }